Siponimod pharmacokinetics, safety and tolerability in combination with the CYP2C9/3A4 inducer, rifampin in healthy subjects

被引：0
|
作者：
Gardin, A. [1 ]
Gray, C. [2 ]
Neelakantham, S. [3 ]
Huth, F. [1 ]
Davidson, A. M. [4 ]
Dumitras, S. [1 ]
Legangneux, E. [1 ]
Shakeri-Nejad, K. [1 ]
机构：
[1] Novartis Inst Biomed Res, Basel, Switzerland
[2] Novartis Pharmaceut, E Hanover, NJ USA
[3] Novartis Healthcare Private Ltd, Hyderabad, Andhra Pradesh, India
[4] PPD, Austin, TX USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2017年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P796
引用
收藏
页码：409 / 409
页数：1
相关论文
共 50 条
  • [1] Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects
    Gardin, Anne
    Gray, Cathy
    Neelakantham, Srikanth
    Huth, Felix
    Davidson, Antonia M.
    Dumitras, Swati
    Legangneux, Eric
    Shakeri-Nejad, Kasra
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (12) : 1593 - 1604
  • [2] Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects
    Anne Gardin
    Cathy Gray
    Srikanth Neelakantham
    Felix Huth
    Antonia M. Davidson
    Swati Dumitras
    Eric Legangneux
    Kasra Shakeri-Nejad
    European Journal of Clinical Pharmacology, 2018, 74 : 1593 - 1604
  • [3] Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes
    Anne Gardin
    Kasra Shakeri-Nejad
    Andrea Feller
    Felix Huth
    Srikanth Neelakantham
    Swati Dumitras
    European Journal of Clinical Pharmacology, 2019, 75 : 1565 - 1574
  • [4] Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes
    Gardin, Anne
    Shakeri-Nejad, Kasra
    Feller, Andrea
    Huth, Felix
    Neelakantham, Srikanth
    Dumitras, Swati
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 75 (11) : 1565 - 1574
  • [5] Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects
    Gardin, Anne
    Ufer, Mike
    Legangneux, Eric
    Rossato, Gianluca
    Jin, Yi
    Su, Zhenzhong
    Pal, Parasar
    Li, Wenkui
    Shakeri-Nejad, Kasra
    CLINICAL PHARMACOKINETICS, 2019, 58 (03) : 349 - 361
  • [6] Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects
    Anne Gardin
    Mike Ufer
    Eric Legangneux
    Gianluca Rossato
    Yi Jin
    Zhenzhong Su
    Parasar Pal
    Wenkui Li
    Kasra Shakeri-Nejad
    Clinical Pharmacokinetics, 2019, 58 : 349 - 361
  • [7] Is celecoxib an inducer of cytochrome P450 3A4 in subjects carrying the CYP2C9*3 allele?
    Rodrigues, A. David
    Yang, Zheng
    Chen, Cliff
    Pray, Devin
    Kim, Sean
    Sinz, Michael
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (03) : 298 - 301
  • [8] Is celecoxib an inducer of cytochrome P450 3A4 in subjects carrying the CYP2C9*3 allele? Reply
    Eliasson, Erik
    Lundblad, Mia Sandberg
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (03) : 301 - 302
  • [9] Effects of CYP2C9 polymorphism on the pharmacokinetics of irbesartan in healthy Korean subjects
    Kim, Mi-Jung
    Bae, Jung -Woo
    Han, Ho-Kyun
    Choi, Sun-Ok
    Kim, Ok-Hee
    Jang, Choon-Gon
    Lee, Jin-Hee
    Kim, Nam-Tae
    Lee, Seok-Yong
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 231 - 231
  • [10] Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjects
    Helene Sabia
    Gangadhar Sunkara
    Monica Ligueros-Saylan
    Yibin Wang
    Harold Smith
    James McLeod
    Pratapa Prasad
    European Journal of Clinical Pharmacology, 2004, 60 : 407 - 412
12345